joint Protein Central

Investment Areas

Deciphering the entire human genome that consists of approximately 30,000 genes provides limitless opportunities to improve human health. Researchers in the field of regenerative medicine face a unique and complex set of challenges in their efforts to translate stem-cell science and gene-editing technology from research laboratories through clinical trials and ultimately to patients. Nature offers only a finite set of protein ligands to develop signaling molecules. One fundamental industry challenge is in chimera technology to overcome this barrier. JPC plays a pivotal role in breaking through the technological barrier by capturing the Three I's intellectual and financial investments.